FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening
This article was originally published in The Pink Sheet Daily
Executive Summary
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.